Skye Bioscience Financials

SKYE

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$29.9M

YoY+13.6%

Skye Bioscience's EBITDA was -$29.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.6% from the prior year.

Free Cash Flow

-$26.8M

YoY-92.2%

Skye Bioscience generated -$26.8M in free cash flow in fiscal year 2024, representing cash available after capital expenditures. This represents a decrease of 92.2% from the prior year.

Net Income

-$26.6M

YoY+29.4%

Skye Bioscience reported -$26.6M in net income in fiscal year 2024. This represents an increase of 29.4% from the prior year.

EPS (Diluted)

$-0.73

YoY+86.4%

Skye Bioscience earned $-0.73 per diluted share in fiscal year 2024. This represents an increase of 86.4% from the prior year.

Cash & Debt

$68.4M

YoY+5345.1%

5Y CAGR+106.3%

10Y CAGR+78.6%

Skye Bioscience held $68.4M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

31M

YoY+150.8%

5Y CAGR-29.9%

10Y CAGR+6.8%

Skye Bioscience had 31M shares outstanding in fiscal year 2024. This represents an increase of 150.8% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$18.7M

YoY+221.4%

5Y CAGR+52.9%

10Y CAGR+55.4%

Skye Bioscience invested $18.7M in research and development in fiscal year 2024. This represents an increase of 221.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$1.6M

YoY+12681.1%

10Y CAGR+52.7%

Skye Bioscience invested $1.6M in capital expenditures in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 12681.1% from the prior year.

SKYE Income Statement

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$18.7M+221.4%	$5.8M-3.2%	$6.0M+105.1%	$2.9M+50.8%	$1.9M-13.1%	$2.2M
SG&A Expenses	$17.7M+125.7%	$7.9M+28.8%	$6.1M+24.0%	$4.9M+13.2%	$4.3M-1.1%	$4.4M
Operating Income	-$30.2M+13.1%	-$34.7M-89.7%	-$18.3M-133.3%	-$7.8M-24.8%	-$6.3M+5.2%	-$6.6M
Interest Expense	$749K-17.3%	$906K+36.3%	$665K-13.5%	$769K+8.9%	$706K-29.4%	$1.0M
Income Tax	$10K+179.8%	$4K-46.6%	$7K+221.0%	$2K+31.3%	$2K0.0%	$2K
Net Income	-$26.6M+29.4%	-$37.6M-93.2%	-$19.5M-128.6%	-$8.5M-29.9%	-$6.6M-723.7%	$1.1M
EPS (Diluted)	$-0.73+86.4%	$-5.37+38.8%	$-8.77-43750.0%	$-0.02+33.3%	$-0.03+40.0%	$-0.05

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q4'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$9.4M-34.7%	$14.3M+99.2%	$7.2M	N/A	$4.9M+19.7%	$4.1M+109.5%	$1.9M	N/A
SG&A Expenses	$3.9M0.0%	$3.9M-14.4%	$4.6M	N/A	$4.6M+7.2%	$4.3M+2.9%	$4.2M	N/A
Operating Income	-$13.3M+27.3%	-$18.2M-55.1%	-$11.8M	N/A	-$5.0M+40.9%	-$8.4M-36.6%	-$6.2M	N/A
Interest Expense	$0	$0-100.0%	$1K	N/A	-$91K-120.2%	$450K+3.0%	$437K	N/A
Income Tax	$0-100.0%	$3K+70.0%	$2K	N/A	$0-100.0%	$8K+303.6%	$2K	N/A
Net Income	-$12.8M+27.6%	-$17.6M-58.7%	-$11.1M	N/A	-$3.9M+50.7%	-$7.9M-57.4%	-$5.0M	N/A
EPS (Diluted)	$-0.32+27.3%	$-0.44-57.1%	$-0.28	N/A	$-0.10+50.0%	$-0.20-11.1%	$-0.18	N/A

SKYE Balance Sheet

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Total Assets	$72.8M+509.4%	$11.9M+31.1%	$9.1M-7.5%	$9.9M+268.9%	$2.7M+33.8%	$2.0M
Current Assets	$70.8M+507.9%	$11.7M+30.3%	$8.9M-7.0%	$9.6M+260.8%	$2.7M+33.6%	$2.0M
Cash & Equivalents	$68.4M+5345.1%	$1.3M+1.0%	$1.2M-86.1%	$9.0M+263.8%	$2.5M+34.9%	$1.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.6M-67.2%	$14.1M+16.1%	$12.1M+203.7%	$4.0M+79.7%	$2.2M+53.3%	$1.4M
Current Liabilities	$4.3M-68.8%	$13.9M+14.7%	$12.1M+209.8%	$3.9M+397.0%	$787K-18.9%	$971K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$68.2M+3296.9%	-$2.1M+29.1%	-$3.0M-151.3%	$5.9M+1200.9%	$451K-17.7%	$548K
Retained Earnings	-$130.9M-25.5%	-$104.4M-56.4%	-$66.7M-41.2%	-$47.3M-22.0%	-$38.7M-20.4%	-$32.2M

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q4'24
Total Assets	$41.3M-20.8%	$52.2M-19.5%	$64.8M-11.0%	$72.8M-10.8%	$81.5M-6.6%	$87.3M-8.0%	$94.8M+694.2%	$11.9M
Current Assets	$39.9M-21.1%	$50.6M-19.7%	$63.0M-11.0%	$70.8M-11.3%	$79.8M-8.3%	$87.0M-8.0%	$94.6M+711.7%	$11.7M
Cash & Equivalents	$18.4M-22.6%	$23.8M-48.6%	$46.4M-32.1%	$68.4M+1.5%	$67.4M-9.1%	$74.1M-11.1%	$83.3M+6533.2%	$1.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.5M0.0%	$8.5M+53.1%	$5.5M+20.2%	$4.6M-19.5%	$5.7M-60.3%	$14.5M-9.4%	$16.0M+13.4%	$14.1M
Current Liabilities	$8.4M+0.7%	$8.3M+56.3%	$5.3M+22.6%	$4.3M-22.9%	$5.6M-60.7%	$14.3M-9.4%	$15.8M+13.7%	$13.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$32.8M-24.8%	$43.7M-26.3%	$59.3M-13.1%	$68.2M-10.1%	$75.8M+4.1%	$72.8M-7.7%	$78.9M+3800.3%	-$2.1M
Retained Earnings	-$172.4M-8.0%	-$159.7M-12.4%	-$142.1M-8.5%	-$130.9M-8.0%	-$121.2M-3.3%	-$117.3M-7.2%	-$109.4M-4.8%	-$104.4M

SKYE Cash Flow Statement

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$25.2M-80.9%	-$14.0M-9.5%	-$12.7M-96.8%	-$6.5M-6.9%	-$6.1M-0.4%	-$6.0M
Capital Expenditures	$1.6M+12681.1%	$13K-55.3%	$28K-69.1%	$91K+1156.8%	$7K	N/A
Free Cash Flow	-$26.8M-92.2%	-$14.0M-9.3%	-$12.8M-94.5%	-$6.6M-8.3%	-$6.1M	N/A
Investing Cash Flow	-$246K-103.7%	$6.6M+26.5%	$5.2M+5838.6%	-$91K-1156.8%	-$7K	N/A
Financing Cash Flow	$83.6M+408.2%	$16.4M+7975.4%	-$209K-101.6%	$13.1M+95.2%	$6.7M+11.6%	$6.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q4'24
Operating Cash Flow	N/A	N/A	-$9.2M	N/A	N/A	N/A	-$4.7M	N/A
Capital Expenditures	N/A	N/A	$6K	N/A	N/A	N/A	$3K	N/A
Free Cash Flow	N/A	N/A	-$9.2M	N/A	N/A	N/A	-$4.7M	N/A
Investing Cash Flow	N/A	N/A	-$12.8M	N/A	N/A	N/A	$1.1M	N/A
Financing Cash Flow	N/A	N/A	$0	N/A	N/A	N/A	$85.7M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SKYE Financial Ratios

Metric	FY24	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	191.9%
Return on Assets	-36.5%+278.8pp	-315.3%-101.4pp	-213.8%-127.3pp	-86.5%+159.1pp	-245.6%-298.2pp	52.7%
Current Ratio	16.32+15.5	0.84+0.1	0.74-1.7	2.46-0.9	3.38+1.3	2.05
Debt-to-Equity	0.07+6.7	-6.60-2.6	-4.03-4.7	0.68-4.2	4.93+2.3	2.64
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q3'25	Q4'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-30.9%+2.9pp	-33.8%-16.6pp	-17.1%	N/A	-4.8%+4.3pp	-9.1%-3.8pp	-5.3%	N/A
Current Ratio	4.77-1.3	6.09-5.8	11.85-4.5	16.32+2.1	14.19+8.1	6.07+0.1	5.99+5.1	0.84
Debt-to-Equity	0.26+0.1	0.19+0.1	0.09+0.0	0.070.0	0.08-0.1	0.200.0	0.20+6.8	-6.60
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is Skye Bioscience profitable?

No, Skye Bioscience (SKYE) reported a net income of -$26.6M in fiscal year 2024.

What is Skye Bioscience's earnings per share (EPS)?

Skye Bioscience (SKYE) reported diluted earnings per share of $-0.73 for fiscal year 2024.

What is Skye Bioscience's EBITDA?

Skye Bioscience (SKYE) had EBITDA of -$29.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Skye Bioscience's free cash flow?

Skye Bioscience (SKYE) generated -$26.8M in free cash flow during fiscal year 2024, representing cash available after capital expenditures.

What is Skye Bioscience's operating cash flow?

Skye Bioscience (SKYE) generated -$25.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Skye Bioscience's total assets?

Skye Bioscience (SKYE) had $72.8M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Skye Bioscience's capital expenditures?

Skye Bioscience (SKYE) invested $1.6M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Skye Bioscience spend on research and development?

Skye Bioscience (SKYE) invested $18.7M in research and development during fiscal year 2024.

How many shares does Skye Bioscience have outstanding?

Skye Bioscience (SKYE) had 31M shares outstanding as of fiscal year 2024.

What is Skye Bioscience's current ratio?

Skye Bioscience (SKYE) had a current ratio of 16.32 as of fiscal year 2024, which is generally considered healthy.

What is Skye Bioscience's debt-to-equity ratio?

Skye Bioscience (SKYE) had a debt-to-equity ratio of 0.07 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Skye Bioscience's return on assets (ROA)?

Skye Bioscience (SKYE) had a return on assets of -36.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.